The role of the microbiome in NAFLD and NASH.
Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. · 2019
Read The role of the microbiome in NAFLD and NASH. by Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6365925.txt.
Introduction
Kolodziejczyk and co-authors present a review in EMBO Molecular Medicine on gut microbes and fatty liver disease. Nonalcoholic fatty liver disease is now the most common liver disease worldwide. A minority of patients progress to NASH, an inflamed form that can cause cirrhosis and liver cancer.
The review traces how gut microbiota shape liver fat and sugar handling. Microbe-derived compounds also tip the balance between inflammatory and calming signals in the liver. The authors survey evidence on the gut-liver axis and on diet and genetic risk. They close with open questions about how microbes might be targeted to slow the disease.
Catalog record
| CREATOR | Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 74 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The role of the microbiome in NAFLD and NASH By Aleksandra A Kolodziejczyk, Danping Zheng, Oren Shibolet, Eran Elinav Published in: EMBO Molecular Medicine DOI: 10.15252/emmm.201809302 ABSTRACT Abstract Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is characterized by inflammatory changes that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. Recent studies have shown that in addition to genetic predisposition and diet, the gut microbiota affects hepatic carbohydrate and lipid metabolism as well as influences the balance between pro‐inflammatory and anti‐inflammatory effectors in the liver, thereby impacting NAFLD and its progression to NASH. In this review, we will explore the impact of gut microbiota and microbiota‐derived compounds on the development and progression of NAFLD and NASH, and the unexplored factors related to potential microbiome contributions to this common liver disease. Keywords: microbiome/microbiota, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis Subject Categories: Digestive System; Microbiology, Virology & Host Pathogen Interaction GlossaryBacteremiaPresence of bacteria in the blood.Bile acidsA group of molecules synthesized from cholesterol in hepatocytes that are major component of the bile. They function in facilitation of nutrient absorption in the gut and metabolic signaling in several tissues in the body.DysbiosisImbalance in composition of microbiota that has a negative effect on the physiology of the host.Fecal microbiota transplantation (FMT)Medical procedure that involves transfer of fecal matter from a donor or donors into the intestinal tract of recipient.Gut epithelial barrierA layer of epithelial cells of the gut that forms a physical barrier between contents of the gut lumen and the host while allowing transport of desired molecules such as nutrients.Gut–liver axisThe interaction between physiology of the gut and the liver that is based on the physical connection between these organs via portal vein.Histone deacetylases (HDACs)Family of enzymes that cleave acetyl group from histones resulting in more positive charge of histone tails and tighter binding of histones to negatively charged DNA.InflammasomeA term describing multiprotein complexes formed in response to variety of signals such as pathogens as well as sterile stress signals and result in secretion of pro‐inflammatory signals such as IL‐1β or IL‐18 and eventually induction of pyroptosis.Intestinal bacterial outgrowthAbnormally high amount of bacteria present in the intestine.Kupffer cellsMacrophages of the liver.NAFLDPresence of at least 5% hepatic steatosis in patients without excessive alcohol consumption, including the entire spectrum of fatty liver disease ranging from simple fatty liver to nonalcoholic steatohepatitis, fibrosis, and cirrhosis.NASHPresence of at least 5% hepatic steatosis with histological characterization of liver inflammation and hepatocyte injury with or without fibrosis.Oxidative stressA situation when there are more free radicals produced than the cell can neutralize with antioxidants. In this situation, free radicals interact and damage cellular components such as proteins, lipids, or nucleic acids.Reactive oxygen species (ROS)Unstable, very reactive molecules containing oxygen, such as peroxide, superoxide, hydroxyl radical.S‐adenosyl methionine (SAM) cycleReactions that produce, consume, and regenerate S‐adenosyl methionine. Regeneration of SAM allows it to function as a key donor of methyl group in the cell.Short‐chain fatty acidsFatty acids with less than six carbon atoms.SteatosisA process defined by accumulation of excessive amount of lipids in the liver cells, mainly inside the hepatocytes. INTRODUCTION NAFLD and NASH Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of at least 5% hepatic steatosis but lacking common causes of secondary hepatic fat accumulation, such as excessive alcohol consumption, chronic viral hepatitis, autoimmune hepatitis, congenital hepatic disorders, or long‐term use of steatosis‐inducing medications (Chalasani et al, 2018). NAFLD often, but not always, occurs together with type 2 diabetes, obesity, dyslipidemia, and hypertension, which constitute cardiometabolic disease (Younossi et al, 2016). The global prevalence of NAFLD is estimated to be 25.24%, with the highest rates in the Middle East (31.79%) and South America (30.45%), followed by Asia (27.37%), North America (24.13%), Europe (23.71%), and Africa (13.48%; Younossi et al, 2016). The incidence of NAFLD is reported to range from 20 to 50 cases per 1,000 person‐years in different countries (Chalasani et al, 2018). These alarming numbers make NAFLD a major clinical and economic burden and the new epidemic in global chronic liver disease (Younossi et al, 2018). A substantial portion of NAFLD patients develop nonalcoholic steatohepatitis (NASH), which is histologically characterized by the presence of hepatic inflammation and liver injury. NAFLD, and particularly NASH, can potentially progress to fibrosis, cirrhosis, and eventually hepatocellular carcinoma (Pais et al, 2013; Calzadilla Bertot & Adams, 2016). In this context, NAFLD is currently the leading cause of chronic liver disease in the USA and Europe. Indeed, NASH‐associated cirrhosis has become the second leading indication for adult liver transplantation in the USA and continues to grow (Wong et al, 2015). Current treatment of NAFLD focuses on lifestyle modification. Liver‐targeted pharmacotherapy is reserved for high‐risk patients and is mostly experimental (Tilg, 2017; Chalasani et al, 2018). The pathogenesis of NAFLD is poorly understood. It is thought to involve complex interactions among genetic susceptibility variants, environmental factors, insulin resistance, and changes in the gut microbiota (Arab et al, 2017). The interplay between these factors results in altered lipid metabolism and excessive lipid accumulation in hepatocytes, culminating in the development of NAFLD. Furthermore, the microbiota is involved in alternating the balance between pro‐inflammatory or anti‐inflammatory signals, thereby contributing to inflammation that may result in progression to NASH. There is thus an urgent need to fully understand the pathogenesis of NAFLD, and the contribution of the microbiome to NAFLD and its progression to NASH, which may enable to improve diagnostics, patient stratification, and identification of new therapeutic targets. The gut microbiome Recent years brought enhancing understanding that the microbiota, an ecosystem consisting of bacteria, archaea, protists, fungi, and viruses living in the human gut, is not an idle bystander but an interconnected, active player in human physiology. The microbiota composition and function are shaped by a variety of host and environmental factors including diet, physical activity, medication, circadian activity, and geographical localization. This complex community of microorganisms bears several folds more genetic information than the human genome, for example, enzymes capable of biochemical functions lacking in the human host, such as deconjugation of primary bile acids or breakdown of indigestible carbohydrates. This person‐specific microbiota configuration cooperates with the unique host genetics in contributing to individualized traits and phenotypes. The gut microbiota actively participates in the digestion of food and facilitates the absorption of the dietary molecules into the portal and systemic circulation (Jumpertz et al, 2011; Ridaura et al, 2013), interacts with the mucosal immune system, to shape development of its antigen recognition, recruitment, proliferation, and effector function, and may impact the host even at far sites from where it actually resides, via modulation of migrating immune cells and through metabolites influxing from the gut into the systemic circulation, where they can affect other distant tissues. The bacterial components and metabolites that cross the epithelial barrier enter the circulation and may feature a systemic bioactive effect. For example, l‐carnitine found in red meat is metabolized by gut bacteria and the host liver to trimethylamine‐N‐oxide (TMAO), which promotes atherosclerosis. Consortia of bacteria of vegans and vegetarians produce less TMAO than those of omnivorous